Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.
Thomas Schinecker
Chief Executive Officer of Roche Diagnostics
Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.
As a leader in diagnostics testing, we have a responsibility to deliver effective solutions for patients fast. Testing is a critical part in fighting this unprecedented global healthcare emergency and we are proud to be able to contribute.
The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.
The cobas® SARS-CoV-2 & Influenza A/B Test is a real-time RT-PCR test intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in nasal or nasopharyngeal swab samples collected from patients.
Both tests can run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems under Emergency Use Authorization. Both tests are also available for countries accepting the CE-mark.
The Elecsys® SARS-CoV-2 Antigen is an immunoassay for the qualitative detection of the SARS-CoV-2 nucleocapsid antigens.
The cobas® SARS-CoV-2 & Influenza A/B Assay is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2., influenza A, and influenza B in nasopharyngeal and nasal swabs from patients suspected of respiratory viral infection.
The test is run on Roche's molecular point-of-care PCR testing solution, the cobas® Liat® System, under Emergency Use Authorization. It is also available for countries accepting the CE-mark.
The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatopgraphic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.
The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.
Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.
The test is intended for the use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.
Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understand which tests are most suitable to use depending on their intended purpose.
*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)
We continue our intensive research and development efforts to bring additional solutions to market to help study the spread of COVID-19 and emerging SARS-CoV-2 variants.
Abbreviations
COVID-19: coronavirus disease 2019
RT-PCR: reverse transcription polymerase chain reaction
